Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
30 June 2020 - 9:00PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, or KORs, today announced the appointment of
Susan Shiff, Ph.D., M.B.A., to its Board of Directors. Dr. Shiff
currently serves as Senior Vice President and Head of the Center
for Observational and Real-World Evidence (CORE) at Merck, known as
MSD outside the United States and Canada.
“Susan brings a wealth of experience in the
health economics and outcomes research (HEOR) and market access
fields, and joins the Board at a pivotal time as we prepare to
transition to a commercial organization,” said Derek Chalmers,
Ph.D., D.Sc., President and Chief Executive Officer of Cara
Therapeutics. “Her insights and skillset will be valuable resources
as we develop and implement evidence-based medicine, patient access
and pricing strategies across the KORSUVA development
pipeline.”
“I am pleased to be joining the Cara Board at
such an exciting time, as the Company prepares to submit its first
New Drug Application (NDA) to the U.S. Food and Drug Administration
later this year,” said Dr. Shiff. “I look forward to working with
the Cara team to optimize commercialization strategies for all
ongoing development programs.”
Dr. Shiff has over 20 years of experience in the
pharmaceutical industry as a leader in the development and
implementation of evidence, access and pricing strategies for
products globally. Before joining Merck, she served as Vice
President of Global Health Economics, Data Sciences and
Evidence-Based Medicine at Teva Pharmaceuticals. Prior to that, Dr.
Shiff was Vice President of Evidence-Based Medicine and Market
Access in Global Primary Care as well as Vice President of HEOR and
Epidemiology in Emerging Markets at Pfizer. She has also held
senior positions at Roche and Johnson & Johnson. Dr. Shiff
began her career at the Centers for Disease Control and Prevention.
She holds an M.B.A. from Cornell University and a Ph.D. from the
University of California, Los Angeles. Dr. Shiff currently serves
on the Boards of Synthace Limited and the Merck Global Health
Innovation Fund. In 2016, she was selected as one of FiercePharma’s
Top 15 Women in Biopharma, in 2017 Proclinical named her as one of
today's most inspiring women in the pharmaceutical industry and in
2018 CB Insights named CORE as one of the most innovative Corporate
Labs in healthcare.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. In two Phase 3 trials, KORSUVA Injection has
demonstrated statistically significant reductions in itch intensity
and concomitant improvement in quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP). Cara has successfully
completed its Phase 2 trial of Oral KORSUVA for the treatment of
pruritus in patients with CKD and is currently conducting Phase 2
trials of Oral KORSUVA in atopic dermatitis and primary biliary
cholangitis patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
Forward-looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Examples of these
forward-looking statements include statements concerning Cara’s
transition to a commercial organization and the timing of Cara’s
anticipated submission of its first NDA. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Risks are described more fully in Cara's filings with
the Securities and Exchange Commission, including the “Risk
Factors” section of Cara's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2020 and its other documents subsequently
filed with or furnished to the Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Except to the
extent required by law, Cara undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
INVESTOR CONTACT: Jane UrheimStern Investor
Relations, Inc.jane.urheim@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Oct 2023 to Oct 2024